SARS-CoV-2

[Small] Scientists presented a systematic, comparative evaluation of various biologically derived nanoscale vesicles, which may be particularly well suited to sustained or repeated administration in the clinic due to low toxicity, and investigated their potential to inhibit multiple classes of model SARS-CoV-2 virions.

[Science Translational Medicine] The authors used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2.

[Cell Reports] Scientists reconstituted an in vitro pseudovirus-liposome fusion reaction and reported that SARS-CoV-2 wild-type spike was a dynamic Ca2+ sensor, and D614G mutation enhanced dynamic calcium sensitivity of spike protein for facilitating membrane fusion.

[Immunity] Scientists assessed affinity and neutralization potency against the Omicron variant of several hundred naturally expressed memory B cell-derived monoclonal IgG antibodies from vaccinated COVID-19-recovered and -naïve individuals.

[Experimental and Molecular Medicine] Investigators discuss a proposed interaction between SARS-CoV-2 and Toll-like receptor 2 (TLR2) in the central nervous system.

[Cell] Investigators examined antibody and memory B cell responses longitudinally for nine to ten months after primary two-dose SARS-CoV-2 mRNA vaccination and three months after a third dose.